Sage, Biogen's tremor drug hits goal, but 38% of people drop out

Sage, Biogen's tremor drug hits goal, but 38% of people drop out

Source: 
Fierce Biotech
snippet: 

A phase 2 clinical trial of an essential tremor (ET) drug candidate in development at Biogen and Sage Therapeutics has met its primary endpoint. The trial linked SAGE-324 to the hoped-for improvement on an upper limb tremor score, but the side effects proved to be intolerable to some patients.